Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Abstract 4685: The identification of new therapeutic targets in mucinous ovarian carcinoma

Serena Petrella, Marika Colombo, Mirko Marabese, Chiara Grasselli, Andrea Panfili, Ilaria Craparotta, Maria Chiara Barbera, Giada Andrea Cassanmagnago, Marco Bolis, Giovanna Damia

Cancer Res (2024) 84 (6_Supplement): 4685.

https://doi.org/10.1158/1538-7445.AM2024-4685

Published: 22 March 2024

View articletitled, Abstract 4685: The identification of new therapeutic targets in mucinous ovarian carcinoma

Journal Articles

Abstract 945: In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models

Michela Chiappa, Federica Guffanti, Ilaria Mengoli, Maya Ridinger, Giovanna Damia

Cancer Res (2024) 84 (6_Supplement): 945.

https://doi.org/10.1158/1538-7445.AM2024-945

Published: 22 March 2024

View articletitled, Abstract 945: In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models

Journal Articles

Abstract 3237: Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance

Michela Chiappa, Federica Guffanti, Alessandra Decio, Alessandro Aliverti, Francesca Ricci, Eugenio Scanziani, Federica Camin, Ilaria Craparotta, Maria Chiara Barbera, Marco Bolis, Maya Ridinger, Giovanna Damia

Cancer Res (2022) 82 (12_Supplement): 3237.

https://doi.org/10.1158/1538-7445.AM2022-3237

Published: 15 June 2022

View articletitled, Abstract 3237: Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance

Journal Articles

Abstract 3244: Exploring the mechanisms of olaparib resistance in resistant-BRCA1 deficient murine ovarian cells

Michela Chiappa, Martina Anselmi, Luca Russo, Monica Lupi, Nicolò Panini, Federica Guffanti, Giovanna Damia

Cancer Res (2022) 82 (12_Supplement): 3244.

https://doi.org/10.1158/1538-7445.AM2022-3244

Published: 15 June 2022

View articletitled, Abstract 3244: Exploring the mechanisms of olaparib resistance in resistant-BRCA1 deficient murine ovarian cells

Journal Articles

Abstract P5-14-01: Eribulin tolerability and correlation between neuropathy and a set of polymorphisms in metastatic breast cancer patients. Results from the PAINTER (Polymorphism And Incidence of Toxicity in ERibulin treatment) study

Cancer Res (2020) 80 (4_Supplement): P5-14-01.

https://doi.org/10.1158/1538-7445.SABCS19-P5-14-01

Published: 15 February 2020

View articletitled, Abstract P5-14-01: Eribulin tolerability and correlation between neuropathy and a set of polymorphisms in metastatic breast cancer patients. Results from the PAINTER (Polymorphism And Incidence of Toxicity in ERibulin treatment) study

Journal Articles

Abstract 3062: PLK1: a new therapeutic target in mucinous ovarian carcinoma

Roberta Affatato, Rosaria Chilà, Monica Lupi, Valentina Restelli, Mark Erlander, Laura Carrassa, Giovanna Damia

Cancer Res (2019) 79 (13_Supplement): 3062.

https://doi.org/10.1158/1538-7445.AM2019-3062

Published: 01 July 2019

View articletitled, Abstract 3062: PLK1: a new therapeutic target in mucinous ovarian carcinoma

Journal Articles

Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank

Federica Guffanti, Maddalena Fratelli, Monica Ganzinelli, Francesca Ricci, Roberta Affatato, Maria Rosa Cappelletti, Daniele Generali, Francesca Bizzaro, Massimo Broggini, Raffaella Giavazzi, Giovanna Damia

Cancer Res (2017) 77 (13_Supplement): 508.

https://doi.org/10.1158/1538-7445.AM2017-508

Published: 01 July 2017

View articletitled, Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank

Journal Articles

Abstract 2352: Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells

Rosaria Chilà, Nicolò Panini, Eugenio Erba, Giovanna Damia, Massimo Broggini

Cancer Res (2017) 77 (13_Supplement): 2352.

https://doi.org/10.1158/1538-7445.AM2017-2352

Published: 01 July 2017

View articletitled, Abstract 2352: Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells

Journal Articles

Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models

Rosaria Chilà, Federica Guffanti, Terence Hall, Francesca Ricci, Massimo Broggini, Giovanna Damia

Cancer Res (2015) 75 (15_Supplement): 3500.

https://doi.org/10.1158/1538-7445.AM2015-3500

Published: 01 August 2015

View articletitled, Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models

Journal Articles

Abstract 4091: Investigations on the role of epithelial-mesenchymal transition and cancer stem cells in the response to therapy in patient-derived ovarian carcinoma xenografts

Francesca Ricci, Federica Guffanti, Maddalena Fratelli, Broggini Massimo, Giovanna Damia

Cancer Res (2015) 75 (15_Supplement): 4091.

https://doi.org/10.1158/1538-7445.AM2015-4091

Published: 01 August 2015

View articletitled, Abstract 4091: Investigations on the role of epithelial-mesenchymal transition and cancer stem cells in the response to therapy in patient-derived ovarian carcinoma xenografts

Journal Articles

Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

Francesca Ricci, Francesca Bizzaro, Marta Cesca, Federica Guffanti, Monica Ganzinelli, Alessandra Decio, Carmen Ghilardi, Patrizia Perego, Robert Fruscio, Alessandro Buda, Rodolfo Milani, Paola Ostano, Giovanna Chiorino, Maria Rosa Bani, Giovanna Damia, Raffaella Giavazzi

Cancer Res (2014) 74 (23): 6980–6990.

https://doi.org/10.1158/0008-5472.CAN-14-0274

Published: 30 November 2014

View articletitled, Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

Includes: Supplementary data

Journal Articles

Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma

Laura Carrassa, Rosaria Chilà, Alessandra Basana, Francesca Ricci, Federica Guffanti, Monica Lupi, Andrea Rinaldi, Luciano Cascione, Francesco Bertoni, Massimo Broggini, Giovanna Damia

Cancer Res (2014) 74 (19_Supplement): 2766.

https://doi.org/10.1158/1538-7445.AM2014-2766

Published: 01 October 2014

View articletitled, Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma

Journal Articles

Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas

Francesca Ricci, Federica Guffanti, Fratelli Maddalena, Patrizia Perego, Robert Fruscio, Romina Baldo, Sonia Magni, Massimo Broggini, Giovanna Damia

Cancer Res (2014) 74 (19_Supplement): 3760.

https://doi.org/10.1158/1538-7445.AM2014-3760

Published: 01 October 2014

View articletitled, Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas

Journal Articles

Abstract 4699: A siRNA high-throughput screening identified Wee1 as determinant of Chk1 inhibitor sensitivity

Laura Carrassa, Rosaria Chilà, Monica Lupi, Francesca Ricci, Marco Mazzoletti, Cinzia Celenza, Massimo Broggini, Giovanna Damia

Cancer Res (2012) 72 (8_Supplement): 4699.

https://doi.org/10.1158/1538-7445.AM2012-4699

Published: 15 April 2012

View articletitled, Abstract 4699: A siRNA high-throughput screening identified Wee1 as determinant of Chk1 inhibitor sensitivity

Journal Articles

Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1

Gennaro Colella, Giovanna Damia, Maurizio D'Incalci, Roberta Cereda, Ingmar Peitz, Gerhard Kelter, Ennio Cavalletti, Silvano Spinelli, Gabriella Camboni

Cancer Res (2011) 71 (8_Supplement): 595.

https://doi.org/10.1158/1538-7445.AM2011-595

Published: 15 April 2011

View articletitled, Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1

Journal Articles

Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231

Giovanna Damia, Ezia Bello, Gennaro Colella, Alexander Berndt, Maurizio D'Incalci, Ennio Cavalletti, Gabriella Camboni

Cancer Res (2011) 71 (8_Supplement): 2574.

https://doi.org/10.1158/1538-7445.AM2011-2574

Published: 15 April 2011

View articletitled, Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231

Journal Articles

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

Ezia Bello, Gennaro Colella, Valentina Scarlato, Paolo Oliva, Alexander Berndt, Giovanni Valbusa, Sonia Colombo Serra, Maurizio D'Incalci, Ennio Cavalletti, Raffaella Giavazzi, Giovanna Damia, Gabriella Camboni

Cancer Res (2011) 71 (4): 1396–1405.

https://doi.org/10.1158/0008-5472.CAN-10-2700

Published: 14 February 2011

View articletitled, E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

Includes: Supplementary data

Journal Articles

Abstract #3147: DNA damage checkpoint pathways activated in hematopoietic stem cells isolated from umbilical cord blood

Laura Carrassa, Elisa Montelatici, Lorenza Lazzari, Massimo Broggini, Eugenio Erba, Giovanna Damia

Cancer Res (2009) 69 (9_Supplement): 3147.

Published: 01 May 2009

View articletitled, Abstract #3147: DNA damage checkpoint pathways activated in hematopoietic stem cells isolated from umbilical cord blood

Journal Articles

4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms

Sergio Marchini, Giovanna Damia, Massimo Broggini, Giulia Pennella, Marina Ripamonti, Aurelio Marsiglio, Cristina Geroni

Cancer Res (2001) 61 (5): 1991–1995.

Published: 01 March 2001

View articletitled, 4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms

Journal Articles

Prevention of Acute Chemotherapy-induced Death in Mice by Recombinant Human Interleukin 1: Protection from Hematological and Nonhematological Toxicities

Giovanna Damia, Kristin L. Komschlies, Hitoyasu Futami, Timothy Back, M. Eilene Gruys, Dan L. Longo, Jonathan R. Keller, Francis W. Ruscetti, Robert H. Wiltrout

Cancer Res (1992) 52 (15): 4082–4089.

Published: 01 August 1992

View articletitled, Prevention of Acute Chemotherapy-induced Death in Mice by Recombinant Human Interleukin 1: Protection from Hematological and Nonhematological Toxicities

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4685: The identification of new therapeutic targets in mucinous ovarian carcinoma

Abstract 945: In vivo anti-tumor activity of onvansertib, a PLK1 inhibitor, combined with gemcitabine or carboplatin in platinum- resistant ovarian carcinoma patient-derived xenograft models

Abstract 3237: Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance

Abstract 3244: Exploring the mechanisms of olaparib resistance in resistant-BRCA1 deficient murine ovarian cells

Abstract P5-14-01: Eribulin tolerability and correlation between neuropathy and a set of polymorphisms in metastatic breast cancer patients. Results from the PAINTER (Polymorphism And Incidence of Toxicity in ERibulin treatment) study

Abstract 3062: PLK1: a new therapeutic target in mucinous ovarian carcinoma

Abstract 508: DNA repair status in a patient derived ovarian cancer xenobank

Abstract 2352: Effect of inhibition of cell cycle versus transcription cyclin-dependent kinases (CDKs) in ovarian cancer cells

Abstract 3500: Combinations of ARQ087 with chemotherapeutic agents are safe and show a striking antitumor activity in different xenograft models

Abstract 4091: Investigations on the role of epithelial-mesenchymal transition and cancer stem cells in the response to therapy in patient-derived ovarian carcinoma xenografts

Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

Abstract 2766: Inhibition of Chk1 and Wee1 as a new therapeutic approach in Mantle Cell Lymphoma

Abstract 3760: Role of epithelial to mesenchymal transition in response to cisplatin in patient-derived ovarian carcinomas

Abstract 4699: A siRNA high-throughput screening identified Wee1 as determinant of Chk1 inhibitor sensitivity

Abstract 595: E-3810 antitumor activity in human xenografts expressing different levels of FGF receptor 1

Abstract 2574: Striking activity of E-3810 combined with paclitaxel and 5FU in the triple negative breast cancer model MDA-MB-231

E-3810 Is a Potent Dual Inhibitor of VEGFR and FGFR that Exerts Antitumor Activity in Multiple Preclinical Models

Abstract #3147: DNA damage checkpoint pathways activated in hematopoietic stem cells isolated from umbilical cord blood

4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin (PNU-159548), a Novel Anticancer Agent Active against Tumor CellLines with Different Resistance Mechanisms

Prevention of Acute Chemotherapy-induced Death in Mice by Recombinant Human Interleukin 1: Protection from Hematological and Nonhematological Toxicities

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only